Biocept Stock Performance

BIOCQ Stock   0.0001  0.00  0.00%   
Biocept holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 26.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biocept will likely underperform. Use Biocept variance and kurtosis , to analyze future returns on Biocept.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Biocept are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile fundamental indicators, Biocept reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor
1:30
Dividend Date
2020-09-08
Last Split Date
2023-05-17
Begin Period Cash Flow28.9 M
Total Cashflows From Investing Activities-807 K

Biocept Relative Risk vs. Return Landscape

If you would invest  0.01  in Biocept on November 15, 2025 and sell it today you would earn a total of  0.00  from holding Biocept or generate 0.0% return on investment over 90 days. Biocept is currently producing 15.4032% returns and takes up 128.4724% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Biocept, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Biocept is expected to generate 165.41 times more return on investment than the market. However, the company is 165.41 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Biocept Target Price Odds to finish over Current Price

The tendency of Biocept Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.0001 90 days 0.0001 
about 61.44
Based on a normal probability distribution, the odds of Biocept to move above the current price in 90 days from now is about 61.44 (This Biocept probability density function shows the probability of Biocept Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the stock has the beta coefficient of 26.18 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Biocept will likely underperform. In addition to that Biocept has an alpha of 26.2441, implying that it can generate a 26.24 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Biocept Price Density   
       Price  

Predictive Modules for Biocept

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biocept. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Biocept's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.00009450.01
Details
Intrinsic
Valuation
LowRealHigh
0.000.000350.01
Details

Biocept Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Biocept is not an exception. The market had few large corrections towards the Biocept's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biocept, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biocept within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
26.24
β
Beta against Dow Jones26.18
σ
Overall volatility
0.0005
Ir
Information ratio 0.12

Biocept Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biocept for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biocept can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Biocept is way too risky over 90 days horizon
Biocept has some characteristics of a very speculative penny stock
Biocept appears to be risky and price may revert if volatility continues
Biocept has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (14.3 M).
Biocept generates negative cash flow from operations
Biocept has a poor financial position based on the latest SEC disclosures

Biocept Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biocept Stock often depends not only on the future outlook of the current and potential Biocept's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biocept's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding565.1 K
Cash And Short Term Investments12.9 M

Biocept Fundamentals Growth

Biocept Stock prices reflect investors' perceptions of the future prospects and financial health of Biocept, and Biocept fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biocept Stock performance.

About Biocept Performance

Assessing Biocept's fundamental ratios provides investors with valuable insights into Biocept's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biocept is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 11.17  10.61 
Return On Tangible Assets(0.94)(0.98)
Return On Capital Employed(1.45)(1.52)
Return On Assets(0.94)(0.98)
Return On Equity(4.16)(3.96)

Things to note about Biocept performance evaluation

Checking the ongoing alerts about Biocept for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biocept help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biocept is way too risky over 90 days horizon
Biocept has some characteristics of a very speculative penny stock
Biocept appears to be risky and price may revert if volatility continues
Biocept has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (14.3 M).
Biocept generates negative cash flow from operations
Biocept has a poor financial position based on the latest SEC disclosures
Evaluating Biocept's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biocept's stock performance include:
  • Analyzing Biocept's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biocept's stock is overvalued or undervalued compared to its peers.
  • Examining Biocept's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biocept's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biocept's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Biocept's stock. These opinions can provide insight into Biocept's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biocept's stock performance is not an exact science, and many factors can impact Biocept's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Biocept Stock Analysis

When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.